Premium
IC‐P‐123: Spectrometry Detection of Alzheimer Biomarkers in AD in Diabetes
Author(s) -
Frederikse Peter H.,
Feng Yicheng,
Bitel Claudine L.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.138
Subject(s) - biomarker , diabetes mellitus , in vivo , medicine , neuroscience , alzheimer's disease , endocrinology , chemistry , pathology , biology , disease , biochemistry , microbiology and biotechnology
between the individual hypometabolism maps and the AD-like map, was calculated as the sum of the product of z-scores from each cerebral voxel from these two maps. HCI scores were compared between NC, HT and HM groups. Results: While the HM, HT, and NC groups did not differ significantly in their age, gender, educational level, or neuropsychological test scores, the three groups differed significantly in their HCI’s (24.38 6 4.84, 23.58 6 3.59, and 21.80 6 4.09, respectively; ANOVA, p 1⁄4 0.004). Additionally, there was a significant association between HCI’s and APOE e4 gene dose (linear trend, p 1⁄4 0.001). Conclusions: The AD-related HCI in cognitively normal late-middle-aged people is associated with three levels of genetic risk for late-onset AD. This index score offers promise in the pre-symptomatic detection and tracking of AD-associated hypometabolism, assessment of genetic and non-genetic risk factors, and evaluation of promising AD-modifying treatments in pre-symptomatic individuals.